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In Brief
Adam et al. have shown that progressive
diabetes develops if fumarate hydratase
is deleted in mouse pancreatic b cells.
Such b cells exhibit elevated fumarate
and protein succination and show
progressively reduced ATP production
and insulin secretion. The depleted
insulin response to glucose recovers
when diabetic islets are cultured in
reduced glucose.
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http://dx.doi.org/10.1016/j.celrep.2017.08.093SUMMARY
We explored the role of the Krebs cycle enzyme
fumarate hydratase (FH) in glucose-stimulated insu-
lin secretion (GSIS). Mice lacking Fh1 in pancreatic
b cells (Fh1bKO mice) appear normal for 6–8 weeks
but then develop progressive glucose intolerance
and diabetes. Glucose tolerance is rescued by
expression of mitochondrial or cytosolic FH but not
by deletion of Hif1a or Nrf2. Progressive hyperglyce-
mia in Fh1bKO mice led to dysregulated metabolism
in b cells, a decrease in glucose-induced ATP
production, electrical activity, cytoplasmic [Ca2+]i
elevation, and GSIS. Fh1 loss resulted in elevated
intracellular fumarate, promoting succination of
critical cysteines in GAPDH, GMPR, and PARK 7/
DJ-1 and cytoplasmic acidification. Intracellular
fumarate levels were increased in islets exposed to
high glucose and in islets from human donors with
type 2 diabetes (T2D). The impaired GSIS in islets
from diabetic Fh1bKO mice was ameliorated after
culture under normoglycemic conditions. These
studies highlight the role of FH and dysregulated
mitochondrial metabolism in T2D.Cell Report
This is an open access article undINTRODUCTION
Diabetes is an increasing and serious global health and financial
problem (Ashcroft and Rorsman, 2012), characterized by defec-
tive insulin secretion from the b cells of the pancreatic islets,
which causes elevated blood glucose. Mitochondrial production
of ATP plays a key role in glucose-stimulated insulin secretion
(GSIS) (Maechler and Wollheim, 1999); an increase in intracel-
lular ATP closes ATP-sensitive K+ channels (KATP channels) in
the b cell plasma membrane, triggering depolarization and
Ca2+-dependent electrical activity. The resulting rise in cyto-
plasmic Ca2+ initiates exocytosis of insulin granules. In addition
to this ‘‘triggering’’ effect, glucose amplifies insulin secretion at
a stage subsequent to Ca2+ influx. Several intracellular factors
might mediate this amplifying effect, including ATP, NADPH,
and glutamate (Henquin, 2011).
The Krebs-cycle enzyme fumarate hydratase (FH) catalyzes
the hydration of fumarate to malate. FH is also a tumor suppres-
sor, mutated in hereditary leiomyomatosis and renal cell cancer
(HLRCC) (Launonen et al., 2001). Loss of FH activity results in the
intracellular accumulation of fumarate, the stabilization of hypox-
ia-inducible factor 1a (HIF1a), and activation of HIF-dependent
pathways, including glucose metabolism (Adam et al., 2014).
The high levels of fumarate that accumulate in FH-deficient
cells cause post-translational modification of cysteine residues
in proteins to form S-(2-succino)-cysteine (2SC), a processs 20, 3135–3148, September 26, 2017 ª 2017 The Author(s). 3135
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
known as succination (Alderson et al., 2006). This induces loss of
activity of the mitochondrial Krebs-cycle enzyme aconitase (Ter-
nette et al., 2013), activation of the antioxidant response sensor
nuclear factor (erythroid-derived 2)-like 2 (NRF2) (Adam et al.,
2011), and elevation of reactive oxygen species (ROS) signaling
(Sullivan et al., 2013; Zheng et al., 2015). Succination has been
described in fat and skeletal muscle cells of some diabetic
animal models (Nagai et al., 2007; Thomas et al., 2012). Its
functional consequences include inactivation of the glycolytic
enzyme glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
(Merkley et al., 2014; Blatnik et al., 2008).
HIF1a is a known regulator of GSIS (Girgis et al., 2012; Spe´gel
et al., 2011). Deletion of von Hippel-Lindau protein (Vhl), an inte-
gral component of the HIF1a degradation pathway, in b cells
leads to HIF1a stabilization, a switch from oxidative to glycolytic
metabolism and consequent glucose intolerance (Zehetner
et al., 2008; Cantley et al., 2009). The high levels of fumarate
that result from FH loss competitively inhibit the 2-oxogluta-
rate-dependent dioxygenases that catalyze HIF prolyl hydroxyl-
ation. This allows HIF to escape degradation and results in the
activation of HIF target genes (Isaacs et al., 2005; O’Flaherty
et al., 2010), raising the possibility that FH loss might impair insu-
lin secretion via HIF1a stabilization.
We explored the role of FH in insulin secretion using a mouse
model in which Fh1 was deleted specifically in pancreatic b cells
(Fh1bKOmice). These mice had normal glucose tolerance for the
first 6–8weeksof life, and theirbcells hadessentiallynormal prop-
erties, including GSIS, despite the lack of a key Krebs-cycle
enzyme.However, Fh1bKOmice subsequently developed rapidly
progressing diabetes, culminating in severe glucose intolerance,
reduced islet insulin content, and almost complete loss of GSIS.
RESULTS
Mice Lacking Fh1 in Pancreatic b Cells Exhibit
Hif1a-Independent Glucose Intolerance
We generated animals in which Fh1 was deleted specifically in
pancreatic b cells (Fh1fl/flRip2-Cre+/; Fh1bKO mice) by inter-
crossing an Fh1 conditional knockout mouse (Pollard et al.,
2007) withmice expressing Cre recombinase driven by the rat in-
sulin promoter (Rip2-Cre mice; Herrera, 2000). Control (CTL)
mice were either Fh1fl/flRip2-Cre/ or Fh1fl/+Rip2-Cre+/ litter-
mates. Deletion of Fh1 in b cells was confirmed at the protein
level in islets of 9- to 12-week-oldmice (Figure 1). Nomarked dif-
ferences were seen in gross histology between CTL and Fh1bKO
mice in islets (Figures 1A and 1F). Immunohistochemistry (IHC)
showed that all cells in CTL islets exhibited uniform expression
of FH, which was lost within the core of Fh1bKO islets. However,
some islet cells, most likely a and b cells, retained FH (Figures
1B, 1G, and 1J). Fh1 loss and elevated fumarate lead to stabili-
zation of HIF1a and subsequent nuclear localization (Isaacs
et al., 2005; Pollard et al., 2005). Figures 1C and 1H show nuclear
localization of HIF1a in most cells of Fh1bKO islets, but not
in CTL islets or the exocrine pancreas. No marked differences
were observed in insulin or glucagon IHC between CTL and
Fh1bKO islets (Figures 1D, 1E, 1I, and 1J).
Deletion of Fh1 was confirmed in Fh1bKO islets from 9- to 12-
week-old mice at the mRNA level. A small amount of Fh1mRNA3136 Cell Reports 20, 3135–3148, September 26, 2017remained in Fh1bKO islets, likely reflecting its presence in non-b
cells (Figure 1K). Expression of the Hif1a target genes pyru-
vate dehydrogenase kinase 1 (Pdk1) and prolyl hydroxylase
dehydrogenase 3 (Phd3/Egln3) was increased in Fh1bKO islets
(Figure 1K).
Blood glucose levels were measured in free-fed CTL and
Fh1bKO littermates from 6 to 20 weeks. While young (6–8 weeks
of age) Fh1bKO mice were nearly normoglycemic, they subse-
quently (at >9 weeks of age) developed severe hyperglycemia
(>20 mM) (Figure 1L). Plasma glucose in CTL mice was stable
at all ages (<10 mM). For simplicity, here we refer to CTL and
Fh1bKO littermates at 6–8, 9–12, and >15 weeks of age as
stages I–III, respectively, to match the progressive diabetes in
Fh1bKO mice. Stages I (non-diabetic [ND]), II (diabetic), and III
(severely diabetic) have free-fed blood glucose levels of
12.8 mM ± 0.6 mM, 22.6 mM ± 1.2 mM, and 30.4 mM ±
0.9 mM (Figure 1L). The progression of diabetes was confirmed
in glucose tolerance tests, which revealed mild intolerance be-
tween 9 and 12 weeks of age (stage II) and severe intolerance
by 15 weeks (stage III) (Figures 1M and 1N). No age-dependent
deterioration of glucose tolerance was observed in CTL mice.
To assess whether the glucose intolerance of Fh1bKO mice
is mediated by HIF1a stabilization, we crossed Fh1bKO and
Hif1afl/flmice (Cramer et al., 2003) to produce b cell-specific dele-
tion of both Fh1 andHif1a (Fh1Hif1abKOmice). Deletion ofHif1a,
confirmed by loss of HIF1a staining in all nuclei of Fh1Hif1abKO
islets (Figure 1O), did not ameliorate the glucose intolerance of
Fh1bKO mice (Figure 1P). Loss of Fh1 also leads to stabilization
of NRF2 and activation of downstream pathways, typified by
increased expression of Hmox1 (confirmed in Figure S1D)
(Adam et al., 2011). The role of Nrf2 in b cell function is unclear,
proposed to protect from oxidative damage and blunt GSIS
(Uruno et al., 2013). To determine the contribution of Nrf2 to
glucose homeostasis, we crossed Fh1bKO with a constitutive
knockout of Nrf2 (Itoh et al., 1997) to delete both Fh1 and Nrf2
in the b cell (Fh1bNrf2DKO). The glucose intolerance of Fh1bKO
mice was unaltered in the Fh1bNrf2DKO mice (Figure S1A). In
contrast, crossing Fh1bKO mice with mice stably expressing
either full-length human FH (Fh1bKO+FH) or cytoplasmic FH
(FHcyt) (Fh1bKO+FHcyt) (Adam et al., 2013) fully reversed the
glucose intolerance tested in stage III mice and restored the
mRNA expression of Egln3 and Hmox1 (Figures 1Q and S1B–
S1D), and these mice were normoglycemic for >1 year.
Deletion of Fh1 in b Cells Results in Progressive Loss
of GSIS
To explore the cause of glucose intolerance in Fh1bKOmice, we
examined insulin secretion from the perfused pancreas. Glucose
elevation from 1 mM to 6 mM transiently stimulated insulin
release 10-fold in stage II CTL mice but not in Fh1bKO litter-
mates (Figure 2A). Nevertheless, the response to 20mM glucose
was almost superimposable in both genotypes. In stage III
Fh1bKO mice, the response to both 6 mM and 20 mM glucose
was 85% less than in CTL (Figure 2B). Similar effects on GSIS
were obtained in static incubations (Figure S2). The mitochon-
drial substrate a-ketoisocaproic acid (a-KIC) stimulated insulin
secretion5-fold in CTL islets but had no effect in Fh1bKO islets
(Figure S2).
Figure 1. Fh1 Loss in Pancreatic b Cells
Results in Progressive Hif1a-Independent
Glucose Intolerance
(A–J) Histological analysis of pancreatic islets from
stage II CTL (A–E) and Fh1bKO (F–J) mice (n = at
least 10 islets from each of 10 mice per genotype).
(A and F) H&E staining of CTL and Fh1bKO,
respectively. (B–E and G–J) Immunohistochem-
istry (IHC) for FH (B andG), HIF1a (C and H), insulin
(D and I), and glucagon (E and J) in CTL (B–E) and
Fh1bKO (G–J). Scale bar, 50 mm (all panels).
(K) mRNA levels of Fh1, Pdk1, and Egln3 relative to
Actb (b-actin) in stage II CTL (black) and Fh1bKO
islets (gray). (n = 30–50 islets in 5 experiments
from a total of 10 animals of each genotype).
xxxp < 0.0001.
(L) Free-fed blood glucose measured in different
aged CTL (blue) and Fh1bKO mice (red). Stages I,
II, and III are identified (n > 200 Fh1bKO mice, and
n > 50 CTL mice). xp < 0.0001.
(M and N) Intraperitoneal glucose tolerance test
(IPGTT) performed in (M) stage II CTL (blue; n = 15)
and Fh1bKO (red; n = 10) mice and (N) stage III
mice (n = 7 per group). xp < 0.05.
(O) IHC for HIF1a in pancreas of stage III Fh1bKO
(top) and Fh1HifabKO (bottom) mice (n = at least
10 islets from each of 4 mice per genotype). Scale
bar, 50 mm.
(P) IPGTT performed in stage III CTL, Fh1bKO,
Hif1aKO, and Fh1Hif1abKO mice. #p < 0.05,
comparing Fh1bKO or Fh1Hif1abKO versus CTL
or Hif1aKO; Fh1bKO versus Fh1Hif1abKO and
CTL versus Hif1aKO are not significant (n = at least
5 mice per genotype).
(Q) Reintroduction of FH or FHcyt rescued the
glucose intolerance of Fh1bKO mice. IPGTT
performed on stage III CTL, Fh1bKO, CTL+FH,
CTL+FHcyt, Fh1bKO+FH, and Fh1bKO+FHcyt
mice. #p < 0.0001, Fh1bKO versus all other groups
(n = 6–8 mice per genotype).
Arrows in (H) and (O) point to nuclei. Error bars
represent ± SEM. See also Figure S1.These differences in insulin release correlated with a reduction
in insulin content. In islets from stage II mice, insulin content and
insulin granule density were reduced by 50% in Fh1bKO islets
(Figures 2C–2E). Pancreatic insulin content was 97% less in
stage III Fh1bKO mice, compared to CTL littermates (Figure 2F),
and there was a marked decrease in insulin-positive cells (Fig-
ure 2G). When insulin secretion data are normalized to basal
values, secretion from stage II Fh1bKO islets remains strongly
reduced, suggesting that there is a functional defect (Figure S2).
Fh1bKO Islets Exhibit Dysregulated Metabolism
As mitochondrial metabolism plays a key role in GSIS (Ashcroft
and Rorsman, 2012) and Fh1 deletion disrupts the Krebs cycle,
we analyzed glucose utilization (3H2O production, reflecting
combined flux through the glycolytic and pentose phosphate
pathways) and oxidation (CO2 production, reflecting mitochon-
drial metabolism) (Hellman et al., 1971). In both CTL and Fh1bKO
stage II islets, glucose oxidation increased 4-fold when glucose
was increased from 1 to 20 mM (Figure 3A). Glucose utilizationalso increased 4-fold, but the effect was 35%–40% greater in
Fh1bKO than CTL islets (Figure 3B), suggestive of increased aer-
obic glycolysis (O’Flaherty et al., 2010).
Metabolite analysis in islets from stage II mice confirmed an
overall pattern of changes similar to that observed in other FH-
deficient cells (Adam et al., 2011; Frezza et al., 2011). In partic-
ular, levels of fumarate, argininosuccinate, and adenylosucci-
nate were increased, and aspartate was reduced (Figure 3C;
Table S1), indicating that FH loss leads to stimulation of the
urea cycle/arginine biosynthesis pathway (Adam et al., 2013;
Zheng et al., 2013). Levels of AMP, uridine monophosphate
(UMP), and guanosine monophosphate (GMP) were decreased,
suggesting both purine and pyrimidine metabolism are compro-
mised as a consequence of aspartate depletion, but likely reflect
altered adenylosuccinate metabolism due to elevated fumarate
(Bulusu et al., 2011). Importantly, no difference was observed
in oxidized or reduced glutathione between CTL and Fh1bKO is-
lets, suggesting no major change in ROS or ROS signaling (Sul-
livan et al., 2013). Islet fumarate and argininosuccinate contentCell Reports 20, 3135–3148, September 26, 2017 3137
Figure 2. Deletion of Fh1 in b Cells Impairs
Insulin Secretion
(A and B) Insulin secretion from the perfused
pancreata of stage II (A) and stage III (B) Fh1bKO
mice (red) and CTL mice (black) (n = 3 mice
for each genotype and age) in response to 1, 6,
and 20 mM glucose. Statistical significances are
omitted for clarity.
(C) Insulin content of islets from stage II CTL mice
(black; n = 10 experiments; n = 10 mice) and
Fh1bKO mice (gray; n = 14 experiments; n = 22
mice). xxxp < 0.0001.
(D) Electron micrographs of b cells from CTL and
Fh1bKO mice. Abbreviations: g, insulin secretory
granules; m, mitochondrion; n, nucleus. Scale
bars, 500 nm.
(E) Insulin granule density measured in electron
micrographs of b cells from stage II Fh1bKO (gray)
and CTL (black) mice (25–30 b cells in 3–5 islets
per genotype), xxxp < 0.001.
(F) Pancreatic insulin content of stage III CTL
(black, n = 5) and Fh1bKO (gray, n = 10) mice.
xxxxp < 0.0001.
(G) Representative examples of insulin IHC in
stage III Fh1bKO andCTL islets (n > 100 islets from
n > 10 mice of each genotype). Scale bar, 50 mm.
Error bars represent ± SEM. See also Figure S2.were normalized following re-expression of either FH or FHcyt in
mice (Figures S3A and S3B).
The lack of FH means there is a loss of Krebs-cycle intermedi-
ates for every glucosemolecule entering themitochondria. Since
metabolism might be maintained by enhanced utilization of
amino acids (anaplerosis), we measured 16 key amino acids in
islets at both 1 mM and 20 mM glucose. Glucose elevation
increased levels of 15 amino acids in CTL islets but had little ef-
fect in stage II Fh1bKO islets (Figures 3D, S3C, and S3D).
Glutamate may play a key role in both glucose- and incretin-
induced insulin secretion, via the amplifying (non-KATP-depen-
dent) pathway (Maechler and Wollheim, 1999). Because the
glucose-induced increase in glutamate was lower in Fh1bKO is-
lets than in CTL islets (Figure 3D), we investigated the amplifying
pathway of insulin secretion using islets from stage II animals
depolarized with 70 mM extracellular K+ (to test the amplifying
effect of glucose). Increasing glucose from 2 mM to 20 mM
amplified insulin secretion by 600% in CTL islets but only by3138 Cell Reports 20, 3135–3148, September 26, 2017150% in Fh1bKO islets (Figure 3E). Addi-
tion of exogenous membrane-permeable
dimethyl glutamate (DMG; 5 mM) had no
effect in CTL islets at either 2 mM or
20 mM glucose but potentiated GSIS in
Fh1bKO islets in response to 20 mM
glucose (Figure 3E). This suggests that
the lack of intermediates, including gluta-
mate, may underlie the impaired insulin
release of Fh1bKO islets. Exogenous
membrane-permeable dimethyl fumarate
(DMF; 5 mM) did not inhibit insulin secre-
tion in CTL islets (Figure 3F), indicatingthat the acute increase of intracellular fumarate in Fh1bKO islets
is not the cause of the impaired GSIS.
Some aspects of altered metabolism in Fh1bKO islets were
also investigated by comparing glutamine (m0 to m+5) and
glucose (m0 to m+6) isotopomers in islets from stage II Fh1bKO
and CTL mice incubated in 1 mM or 20 mM glucose with either
[U-13C5]-glutamine or
13C6-glucose (Figure S4). Increased levels
of fumarate and argininosuccinate, derived from glutamine, were
observed in islets subsequently exposed to 20 mM glucose (Fig-
ures S4C and S4D). Islets cultured at 20 mM glucose utilized
glutamine to generate uridine 5’-diphosphate (UDP)-N-acetyl-
glucosamine (Figures S4H and S4M), a precursor for synthesis
of glycosaminoglycans, proteoglycans, and glycolipids (Bond
and Hanover, 2013). Substitution of the isotopomers m+2,
m+3, m+4, and m+5 for the naturally occurring m+0 and m+1
forms was increased significantly in both glutamate and aspar-
tate in both CTL and Fh1bKO in islets incubated with 20 mM
glucose (Figures S4J, S4L, S4N, and S4O).
Figure 3. Ablation of Fh1 Causes Dysregulated Metabolism
(A) Glucose oxidation in stage II Fh1bKO and CTL islets (n = 7 CTL and n = 16 Fh1bKOmice in 3 experiments) at 1mM and 20mMglucose. **p < 0.01 versus 1mM
glucose; not significant between CTL and Fh1bKO islets.
(B) Glucose utilization in CTL and Fh1bKO islets from stage II mice (n = 7mice of each genotype in 3 experiments) at 1mMand 20mMglucose. ***p < 0.001 versus
1 mM glucose; xxp < 0.01 between CTL and Fh1bKO at 20 mM glucose.
(C) Heatmap of metabolites (measured by CE-TOFMS) that show significant concentration differences between islets from stage II CTL (n = 8 mice) and Fh1bKO
(n = 7 mice) mice incubated at 5 mM glucose for 1 hr. Red and green for Fh1bKO islets indicate metabolites that are significantly increased or decreased,
respectively, versus CTL islets (p < 0.05); Student’s t test. Each column represents values for islets from one animal. Absolute values are given in Table S1. Branch
points indicate metabolites linked in common pathways.
(D) Amino acid content in islets of stage II Fh1bKO (gray; n = 12) and CTL (black; n = 8)mice at 20mMglucose, expressed relative to that at 1mMglucose (20G/1G)
(n = 30 islets per group analyzed in triplicate in 5 experiments). Abbreviations: Asp, aspartate; Glu, glutamic acid; Ser, serine;Gln, glutamine; His, histidine; Gly,
(legend continued on next page)
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Progressive Loss of GSIS in Fh1bKO Mice Correlates
with Reduced ATP Production and b Cell Electrical
Activity
Next, we compared the effects of glucose on ATP production
and electrical activity in CTL and Fh1bKO mice. The glucose-
induced increase in the ATP/ADP ratio was identical in stage I
Fh1bKO and CTL islets (Figure 4A). However, b cells in islets
from stage III Fh1bKO mice exhibited far smaller glucose-
induced increases in the ATP/ADP ratio than age-matched
CTL b cells (Figures 4B and 4C).
Glucose-induced electrical activity in b cells from stage II
Fh1bKO mice was similar to that of CTL islets (Figure 4D). How-
ever, clear differences were observed in stage III mice. Whereas
CTL b cells responded to 20 mM glucose with membrane depo-
larization and action potential firing, b cells in stage III Fh1bKO
islets were refractory to glucose stimulation (Figure 4E). In
such glucose-unresponsive Fh1bKO b cells, electrical activity
was elicited by the KATP-channel blocker tolbutamide. Together,
these data suggest that glucose is unable to inhibit KATP chan-
nels in stage III Fh1-deficient b cells, because ATP generation
is reduced.
Fh1 Deletion Causes Disruption of b Cell Mitochondrial
Ultrastructure
The morphology, size, and distribution of mitochondria in b cells
of stage II mice were analyzed by electron microscopy. Whereas
mitochondria in CTL b cells had normal morphology with clear
cristae, many mitochondria in Fh1bKO b cells were swollen
without clear cristae, and some were very large (>1.25 mm in
diameter). There was larger range in the mitochondrial area in
Fh1bKO b cells, suggesting an imbalance between mitochon-
drial fission and fusion (Figures S5A and S5B). Mitochondria in
islets from Fh1bKO+FH (full-length FH rescue) or Fh1bKO+FHcyt
(cytoplasmic FH rescue) mice were similar to those of CTL mice
(Figure S5B).
Protein Succination in Diabetic Islets
Fumarate reacts with cysteine residues in proteins in a non-enzy-
matic process known as succination. Using an antibody (2SC)
that labels succinated proteins specifically (Blatnik et al.,
2008), we confirmed that succination was detected in Fh1bKO
b cells and not in CTL b cells (Figures 5A and 5B).
Culture of adipocytes in high glucose elevates fumarate and
results in protein succination (Nagai et al., 2007). Therefore, we
determined quantitatively whether hyperglycemia would in-
crease fumarate in islets. Fumarate levels were100-fold higher
in stage II Fh1bKO islets, even after 1 hr incubation at 1 mM
glucose, yet they were further increased at 20 mM glucose (Fig-
ure 5C). Glucose also increased fumarate levels in CTL islets; 1 hrglycine; Thr, threonine; Arg, arginine; Tau, taurine; Ala, alanine; Tyr, tyrosine; GA
Leu, leucine.
(E) Insulin secretion from islets from stage II Fh1bKO (gray) and CTL (black) islets (
2 mM or 20mM glucose and 5mM dimethylglutamate (DMG), as indicated. **p < 0
xxp < 0.01 CTL versus Fh1bKO in 20 mM glucose.
(F) Insulin secretion in wild-type islets (n = 13 experiments; n = 3mice) at 1mM and
or better versus 1 mM glucose.
Error bars represent ± SEM. See also Figures S3 and S4 and Table S1.
3140 Cell Reports 20, 3135–3148, September 26, 2017incubation at 20 mM glucose increased fumarate levels 12-fold,
compared to islets incubated at 1 mM glucose. This was not due
to a reduction in FH (Figure 5D) and, thus, is likely a consequence
of the enhanced glucose metabolism. Similar acute (1 hr) effects
of high glucose on fumarate content were observed in ND human
islets (Figures 5E and 5F). Interestingly, the fumarate content of
islets from donors with type 2 diabetes (T2D) was higher than
that in ND islets, and high glucose produced no further increase
(Figure 5F).
Tandem mass spectrometry (MS/MS) analysis of islets from
stage II Fh1bKO mice islets detected succination of key
cysteine residues in glyceraldehyde 3-phosphate dehydroge-
nase (GAPDH; residue C150) (Figures 5G and 5H), guanosine
monophosphate reductase (GMPR; C186) (Figure S6A; Table
S2), and Parkinson’s disease (autosomal recessive, early onset)
7 (PARK 7/DJ-1; C106). Succination of PARK7/DJ-1 (C106) was
also observed in islets from a human T2D donor (Figure S6B;
Table S2).
Succination of residue C150 of GAPDH was increased by
270% in Fh1bKO islets (Figures 5G and 5H). Succination of
GAPDH, detected in the gastrocnemius muscle of diabetic
rats, has been shown to reduce enzyme activity (Blatnik et al.,
2008). This might limit glucose flux through glycolysis, leading
to accumulation of upstream glycolytic 3- and 6-carbon interme-
diates. We tested the possible functional consequences by
culturing CTL islets for 24 hr in the presence of 10 mM of the
triose D-glyceraldehyde. This resulted in the complete loss of
GSIS and correlated with a slight increase in islet insulin content
(Figures S7A and S7B).
Impact of Fh1 Deletion on Cytosolic Calcium and pH
Links have been proposed between glucose and pHi (Shepherd
and Henquin, 1995). The loss of glucose- and Ca2+-dependent
electrical activity in stage III Fh1bKO b cells is predicted to cause
an alteration in Ca2+ handling. Intracellular accumulation of
fumarate, the anion of fumaric acid, may lower cytoplasmic pH
(pHi) and thereby compromise GSIS, effects compounded by
the inhibition of GAPDH and accumulation of acidic trioses.
Therefore, we performed parallel measurements of [Ca2+]i and
pHi in stages I and III Fh1bKO b cells and CTL cells. Changes
in [Ca2+]i were similar in stage I CTL and Fh1bKO b cells (Figures
6A and 6B). Thus, glucose, glyceraldehyde, and high K+-induced
membrane depolarization increased [Ca2+]i. Tolbutamide had lit-
tle additional stimulatory effect on [Ca2+]i when tested in the
presence of 20 mM glucose (cf. Figure 4E). Although basal pHi
was slightly lower in b cells from stage I Fh1bKO mice than in
CTL cells (as expected from the elevated fumarate), the re-
sponses to glucose and glyceraldehyde were similar (Figures
6A, 6B, and 6E): glucose and glyceraldehyde lowered pHiBA, gamma aminobutyric acid; Val, valine; Phe, phenylalanine; Ile, isoleucine;
n = 4 experiments; n = 3 mice per genotype) in the presence of 70 mM KCl and
.01 versus 2mM glucose in Fh1bKO; ***p < 0.0001 versus 2 mM glucose (CTL);
20mMglucose with the addition of dimethyl fumarate (5mMDMF). **p < 0.001
Figure 4. Fh1bKO b Cells Exhibit Impaired Electrical Activity and
Reduced ATP Production with Age
(A) Glucose-induced changes in the ATP/ADP ratio in b cells from stage I CTL
(black) and Fh1bKO (red) mice. Each trace is the average of >200 cells.
(B) Same as in (A) but using islets from stage III CTL and hyperglycemic
Fh1bKO mice. Each trace is the average of >200 cells.
(C) Cytoplasmic ATP/ADP ratio at 1 mM and 20 mM glucose in islets from
stage I and stage III Fh1bKO and age-matched CTL mice (n = 4 mice per
genotype, >200 cells per mouse). Responses are normalized to the ratio at
1 mM glucose. *p < 0.05 versus CTL; #p < 0.05 versus basal (3 mM glucose).
Error bars represent ± SEM.
(D) Glucose-induced electrical activity in b cells of stage II CTL or Fh1bKO
b cells. Traces are representative of 5 (CTL) or 4 (Fh1bKO) b cells from at least
3 mice of each genotype.
(E) Same as in (D) but using islets from stage III CTL and Fh1bKOmice. Traces
are representative of 5 (CTL) or 4 (Fh1bKO) b cells from at least 3 mice of each
genotype.reversibly in both CTL and Fh1bKO b cells, and high-[K+]o depo-
larization produced a further drop in pHi.
The [Ca2+]i and pHi responses of CTL b cells did not change
with age, in contrast to the responses of those of stage III
Fh1KbO mice (Figures 6C–6E). Both glucose and D-glyceralde-
hyde were without effect on [Ca2+]I, and tolbutamide was only
effective in some b cells. However, high [K+]o depolarization
(which bypasses metabolism) consistently increased [Ca2+]i.
Basal pHi was lower in stage III Fh1bKO b cells than either CTLor stage I Fh1bKO b cells (Figures 6C–6E). Increasing glucose
to 20 mM or the addition of 10 mM D-glyceraldehyde reduced
pHi in CTL b cells but did not cause further acidification in stage
III Fh1bKO b cells (Figures 6D and 6E).
Impaired GSIS in Fh1bKO Islets Is a Consequence of
Hyperglycemia
We reasoned that the deterioration of GSIS in Fh1bKO islets over
time might be a consequence of the progressive hyperglycemia
(Brereton et al., 2014). We tested whether the impairment of
GSIS could be reversed. Freshly isolated islets from stage III
Fh1bKO mice were refractory to 6 mM glucose, and the
response to 20 mM glucose was only 30% of that seen in CTL
islets (Figure 7A), echoing the data from the perfusion experi-
ments (Figure 2B).
After culture at 12mMglucose for65 hr, secretory responses
in CTL islets were essentially the same as in freshly isolated
islets. However, GSIS at 20 mM glucose was dramatically
improved in Fh1bKO islets and approached that of the CTL islets
(Figure 7B). Insulin content was 35% lower in Fh1bKO than in
CTL islets (Figure 7C).
Finally, we tested whether the loss of GSIS in stage III Fh1bKO
islets reflects a direct ‘‘glucotoxic’’ effect or is related to acceler-
ated glucose metabolism. Distinct from what was seen following
culture at 12mMglucose (Figures 7A and 7B), islets from stage III
Fh1bKO mice cultured for 3 days at 20 mM glucose showed
no recovery of GSIS. By contrast, islets cultured in the presence
of the glucokinase inhibitor mannoheptulose (Zelent et al.,
2005; Coore and Randle, 1964) exhibited some (limited) glucose
responsiveness (Figure 7D).
DISCUSSION
We show here that lack of the Krebs-cycle enzyme FH causes a
progressive deterioration of b cell function, resulting in severe dia-
betes associated with impaired oxidative metabolism, ATP pro-
duction, intracellular calciumhandling, andcytosolic acidification.
Distinct from themousemodel in which Vhl is deleted in b cells
(Zehetner et al., 2008; Cantley et al., 2009), we found that the dia-
betes associated with Fh1 loss is Hif1a and Nrf2 independent.
Our data are consistent with earlier observations that, while Fh1
deletion leads to the accumulation of fumarate, and HIF1a is sta-
bilized, many associated functional changes are independent of
HIF1a (O’Flaherty et al., 2010; Adam et al., 2013; Ternette et al.,
2013). Similar to previous studies, we were unable to detect
HIF1a in normal b cells, anddeletion ofHif1a alone did not disrupt
glucose homeostasis (Zehetner et al., 2008; Cantley et al., 2009).
However, it remains unclear whether b cell dysfunction and dia-
betes are caused by HIF1a stabilization or vice versa (Cantley
et al., 2010; Girgis et al., 2012). In the Fh1bKO mouse, loss of
glucose regulation appears entirely attributable to FH. The hyper-
glycemia that develops may drive HIF1a stabilization, perhaps
compounding GSIS impairment further in a feedback loop.
Why Do Young (Stage 1) Fh1bKO Mice Have Normal
Glucose Tolerance?
Given the importance of mitochondrial metabolism for insulin
secretion, the mild phenotype of stage I Fh1bKO mice wasCell Reports 20, 3135–3148, September 26, 2017 3141
(legend on next page)
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surprising, not least as Fh1 deletion led to >100-fold accumula-
tion of fumarate, consistent with arrest of the Krebs cycle at FH.
Because insulin secretion was unimpaired, this suggests that re-
filling of Krebs-cycle intermediates (anaplerosis) must occur
distal to FH. Labeling experiments in mouse embryonic fibro-
blasts (MEFs) lacking Fh1 show that fumarate exits the mito-
chondria to the cytoplasm but is then metabolized to aspartate
via the urea cycle, which re-enters the Krebs cycle (Adam
et al., 2013). Studying metabolism in murine pancreatic islets is
difficult because of the limited amounts of material available,
especially from the diabetic islets. Our analyses of Fh1bKO islets
by capillary electrophoresis time of flight MS (CE-TOFMS) indi-
cate similar disruption of the urea cycle and purine metabolism
and explain, in part, why the diabetic phenotype of Fh1bKO
mice can be rescued by re-expression of cytosolic FH. More-
over, Fh1bKO islets exhibit increased utilization and oxidation
of glucose, consistent with aerobic glycolysis, recapitulating
previous observations made when Fh1 was deleted in MEFs
and mouse kidney (O’Flaherty et al., 2010; Adam et al., 2013).
Normally, excess Krebs-cycle reactants are used to produce
amino acids via cataplerosis (Choi et al., 2011; MacDonald
et al., 2005). However, in Fh1bKO islets, amino acid content
tended to be reduced, and glucose did not increase the content
of several amino acids; for example, glutamate. This is of interest
because glutamate has been implicated in the amplification of
GSIS (Maechler andWollheim, 2000). Exogenous dimethyl gluta-
mate restored GSIS in Fh1bKO islets but had no effect in CTL is-
lets. These data support the idea that glutamate functions as an
‘‘amplification signal.’’ Another possibility is that exogenous
glutamate may restore GSIS by feeding into the Krebs cycle
and partially restoring mitochondrial metabolism (Frezza et al.,
2011).
Despite the 50% reduction in insulin content, the response
to 20 mM glucose was maintained in stage II Fh1bKO mice. We
speculate that Fh1bKO b cells may compensate for the reduc-
tion of insulin content by stimulation of insulin exocytosis.
Fh1bKO islets contain significantly elevated levels of adenylo-
succinate, which has been proposed to stimulate exocytosisFigure 5. Succination Is a Feature of Elevated Fumarate
(A) IHC for 2SC in islets from stage II CTL (left) and Fh1bKO (right) islets (n > 300
(B) Immunofluorescence for 2SC (green), insulin (red), glucagon (purple), nuclei (bl
islets from n > 10 Fh1bKO mice). Scale bar, 20 mm.
(C) Fumarate content determined by CE-TOFMS in islets from stage II Fh1bKOmic
incubated for 1 hr at 1 mM or 20 mM glucose. **p < 0.01 versus 1 mM glucose;
(D)Western blot of FH protein in islets from stage II CTLmice (all islets from n = 3m
(E) Fumarate content measured by CE-TOFMS of islets from human ND donors (4
glucose.
(F) Fumarate content determined by gas chromatography-mass spectrometry (GC
16.7 mM glucose. Content is expressed relative to that of ND islets at 2.8 mM g
(G and H) MS/MS spectra for the GAPDH-derived peptide IVSNASCTTNCLAPLAK
islets (at least 150 islets per genotype). The calculated peptide mass based on
peptide ion ([M+2H]2+) and the calculated ([M] calc.) and theoretical peptide mas
fragment ions are indicated in the peptide sequence, assigned in the spectrum
ion; *: fragment ionminus NH3; and
2+: doubly charged fragment ion. Both theoreti
ion. Peptide fragments that include the succinated cysteine residue are highlight
Insets in (G) and (H) show the extracted ion chromatograms of the precursor pe
tification of the peptide, corresponding to residues 144–160 of Gapdh, succinated
unmodified peptide was decreased by 70%. PE indicates the modification of cys
only C154 in (H). Error bars represent ± SEM. See also Figure S6 and Table S2.by inhibition of the sentrin/SUMO-specific protease 1 (Gooding
et al., 2015).
Rapid Progression to Diabetes in Stage II Fh1bKO Mice
Once slight hyperglycemia developed, rapid deterioration of gly-
cemic control was observed (up to 10 mM/week). We speculate
that a small elevation of plasma glucose induces a vicious cycle
of impaired insulin secretion and hyperglycemia. In part, this
arises because, as blood glucose increases, more glucose en-
ters metabolism, causing even greater stress on the b cell with
increased fumarate levels. It is possible that metabolism of cyto-
solic fumarate and anaplerosis eventually become unable to
maintain the Krebs cycle and that, once this occurs, rapid dete-
rioration of both GSIS and glucose tolerance occurs.
Why Do Fh1bKO Mice Become Glucose Intolerant?
Our results indicate that Fh1bKO mice eventually develop dia-
betes because glucose is no longer able to stimulate insulin
secretion. This is because of a failure of mitochondrial meta-
bolism that culminates in impaired ATP production, defective
KATP-channel closure, and suppression of electrical activity
and [Ca2+]i.
Why does ATP production fail? Pumping H+ across the inner
mitochondrial membrane, the electron transport chain produces
the alkalinization of the mitochondrial matrix (Wiederkehr et al.,
2009) and membrane hyperpolarization, which are needed to
drive ATP synthesis in b cells. Fumaric acid (C4H4O4) is an acid
with two hydroxyl groups with pKa of 3.0 and 4.4; thus, loss of
FH activity can accordingly be expected to result in acidification
not just of the cytoplasm (experimentally measured) but also of
the mitochondrial matrix.
There is a sigmoidal relationship between glucose concentra-
tion and mitochondrial metabolism (Ashcroft et al., 1970; Hell-
man et al., 1971). At low glucose concentrations, the Krebs
cycle runs at a fairly low rate, and the amount of fumarate gener-
ated and deposited in the cytosol will be low. Thus, if Fh1bKO
mice remain normoglycemic, cytoplasmic acidification will be
modest. In agreement with this idea, glucose-responsive b-cellsislets from 10 mice of each genotype). Scale bar, 20 mm.
ue), and overlay in a representative islet from a stage III Fh1bKOmouse (n > 100
e (gray; all islets from n = 6mice) and CTLmice (black; all islets from n = 6mice)
xxxp < 0.01 versus CTL.
ice) cultured for 24 hr at 5mMor 20mMglucose. Cnx, calnexin, loading control.
donors) incubated for 1 hr at 1 mM or 20 mM glucose. **p < 0.01 versus 1 mM
-MS) in human ND (31 donors) or T2D (7 donors) islets cultured at 2.8 mM and
lucose.
in its non-succinated (G) and succinated (H) forms in stage II Fh1bKO and CTL
the detected m/z (m, mass; z, charge) value of the doubly charged precursor
s ([M] theor.) are stated for both peptide species. Detected N- and C-terminal
and depicted as follows: b: N-terminal fragment ion; y: C-terminal fragment
cal mass (in brackets) and detected mass are given for each assigned fragment
ed in red, while unsuccinated fragments are depicted in green.
ptide from a representative triplicate run of analyzed pancreatic islets. Quan-
at C150, indicate that the succinated peptide was enriched by 270%, while the
teine residues at C150 and C154 to pyridylethyl-cysteine in the inset in (G) and
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Figure 6. Effect of Fh1 Deletion on [Ca2+]i
and pHi in b Cells
(A and B) Top: simultaneous measurements of
[Ca2+]i (green) and pHi (red) in b-cells within intact
pancreatic islets from stage I CTL (A) and Fh1bKO
(B) mice exposed to 3 mM or 20 mM glucose,
10 mM D-glyceraldehyde, 30 mM K+, or 0.1 mM
tolbutamide. The dashed line indicates basal pHi.
Bottom: heatmaps showing pHi (red) and [Ca
2+]i
(green) responses for individual cells (>20 cells
within a single islet). Color intensity indicates
concentration range from low (black) to high
(white). See calibration bars at right.
(C and D) Same as in (A) and (B) but using islets
from stage III CTL (C) and Fh1bKO (D) mice.
(E) Mean ± SEM fluorescence ratio (left) at 3 mM
glucose, with or without 10 mM D-glyceraldehyde
or 20 mM glucose in b cells from stage I (gray bars)
Fh1bKO (n = 95 cells from 2 mice) and stage III
(white bars) Fh1bKO (n = 39 cells from 4 mice)
mouse islets. #p < 0.05 versus basal (3 mM)
glucose and CTL (n = 163 cells from 6 mice; there
was no difference between stage I and stage III
CTL b cells, and data have been pooled for
display). *p < 0.05 versus CTL; {p < 0.05 versus
stage I Fh1bKO b cells. Approximate changes in
calibrated pHi are shown (right).from stage I Fh1bKO mice had a higher pHi than b cells from
stage III mice. At higher plasma glucose levels, mitochondrial
glucose metabolism will accelerate due to the increased sub-
strate, leading to greater fumarate generation, acidification of
both cytoplasmic andmitochondrial matrices, and a progressive
impairment of ATP production. Also, acidification may influence
the activity of other enzymes involved in b cell metabolism with
optimal activity at alkaline pH (e.g., Bernstein and Everse,
1978; Lai and Cooper, 1986; Willson and Tipton, 1980). These
effects may be aggravated by downregulation of key genes
involved in mitochondrial metabolism, as seen in a mousemodel3144 Cell Reports 20, 3135–3148, September 26, 2017of diabetes caused by a gain-of-function
mutation in the KATP channel (bV59M
mice; Brereton et al., 2016). These sce-
narios are not mutually exclusive, and it
is possible that they operate in parallel
and that both contribute to the loss of
ATP production and GSIS. Both these
hypotheses predict that inhibition of
glucose metabolism should exert a pro-
tective effect on b cell metabolism. This
proved to be the case, as GSIS was
restored in Fh1bKO islets following
‘‘normoglycemic’’ culture or culture in
high glucose with the glucokinase inhibi-
tor mannoheptulose.
Fumarate Accumulation Leads to
Protein Succination
Our data demonstrate that elevation of
intracellular fumarate is associated with‘‘hyperglycemia’’ in both mouse and human islets. We detected
succination of critical cysteines in GAPDH, GMPR, and PARK7/
DJ-1 proteins in Fh1bKO islets. Succination of GAPDH has been
reported previously in adipocytes in diabetic db/db and ob/ob
mice. It is a marker of impaired mitochondrial metabolism and
has functional effects (Blatnik et al., 2008; Frizzell et al., 2011).
Reduced PARK7/DJ1 activity is compatible with the small
mitochondria (suggestive of mitochondrial fragmentation and
impaired function) seen in Fh1bKO islets. Interestingly, we found
that fumarate levels are elevated in islets from T2D donors
and may, via succination, explain why expression of PARK7 is
Figure 7. GSIS Dysfunction in Diabetic
Fh1bKO Islets Can BeReversed by ‘‘Normo-
glycemia’’
(A) Insulin secretion from freshly isolated islets
from stage III Fh1bKO (gray) and CTL (black) lit-
termates at 1 mM, 6 mM, or 20 mM glucose
during static incubation (n = 12–18 experimental
groups of islets from at least 8 mice of each ge-
notype in a total of 3 experiments). ****p < 0.0001
versus 1mMglucose; {{{{p < 0.0001 versus 6mM
glucose; xxxxp < 0.0001 versus 20 mM glucose
in CTL.
(B) Insulin secretion from the same islets as in (A)
after 65-hr culture at 12 mM glucose. ***p < 0.001
versus 1 mM glucose; {{p < 0.01 versus 6 mM
glucose; xxxxp < 0.0001 versus 20 mM glucose
in CTL.
(C) Insulin content of islets used in (B).
xxxxp < 0.0001.
(D) Insulin secretion in islets isolated from stage III
Fh1bKO mice measured in static incubations at
1 mM or 20 mM glucose after 72-hr culture at
20 mM glucose with or without 10 mM man-
noheptulose (n = 3 mice). {{{p < 0.001 versus
1 mM glucose; #p < 0.05, and ###p < 0.001 versus
corresponding condition without prior culture in
the presence of mannoheptulose.
Error bars represent ± SEM. See also Figure S7.reduced in T2D islets (Jain et al., 2012). Importantly, it also sug-
gests that mitochondrial metabolism is impaired in islets, leading
to elevated fumarate and succination.
Conclusions
Our studies suggest a cycle in which progressive hyperglycemia
in Fh1bKO mice leads to the deterioration of metabolism, culmi-
nating in the loss of GSIS and frank diabetes. Although b cells
from young Fh1bKO mice are glucose responsive, subtle differ-
ences exist between Fh1bKO and CTL islets. Thus, GSIS is
impaired at 6 mM glucose in Fh1bKO mice, compared to CTL
mice. This defect may underlie the slight elevation in plasma
glucose that precedes the more rapid deterioration in glucose
tolerance. Our hypothesis is consistent with the proposal that
hyperglycemia, via b cell decompensation, initiates a cycle
of progressive hyperglycemia and impaired GSIS (Weir and Bon-
ner-Weir, 2004).
In severely diabetic mice expressing the gain-of-function KATP
channel mutation V59M (Brereton et al., 2014), the adverse
effects on b cell function and insulin content were reversed
following restoration of normoglycemia. Similarly, the severe
impairment of GSIS seen in diabetic (stage III) Fh1bKO islets
was almost fully corrected simply by culturing the islets under
‘‘normoglycemic’’ conditions. This agrees with the report that
GSIS is restored in long-term T2D patients following normaliza-
tion of plasma glucose levels and suppression of hepatic glucose
production induced by a low-calorie diet (Lim et al., 2011).
We propose that the Fh1bKO mouse provides a valuable new
model for T2D. In particular, it is not obese, and the glucose intol-erance develops in an age-dependent fashion. Thus, it provides
a useful tool for studying the progression observed in T2D and to
interrogate the systemic and cellular consequences of metabolic
dysfunction in the pancreatic b cell without the complications of
altered diet and/or obesity.
EXPERIMENTAL PROCEDURES
See also Supplemental Experimental Procedures.
Mice
Animal experimentswere conducted in accordancewith theUKAnimals Scien-
tific Procedures Act (1986) and University of Oxford local ethical guidelines. We
used male and female adult mice of the following strains: Fh1tm1Pjpfl/flRip2-
Cre+/ (Fh1tm1Pjpfl/fl crossed with Tg(Ins2-Cre)23HerrCre recombinase, Rip2-
Cre+/), Fh1tm1Pjpfl/flHif1afl/flRip2-Cre+/, Fh1tm1Pjpfl/flRip2-Cre+/Gt(ROSA)
26Sortm1(CAG-FH)Pjp;Tg(Cdh16-cre)91Igr,Fh1tm1PjpGt(ROSA)26Sortm1(CAG-FH*)Pjp
Tg(Cdh16-cre)91Igr, and Fh1tm1Pjpfl/flRip2-Cre+/Nrf2/ mice (designated
Fh1bKO, Fh1Hif1abKO, Fh1bKO+FH, Fh1bKO+FHcyt, and Fh1b/Nrf2KO,
respectively) and littermate controls (designated CTL). The constitutive Nrf2
KO mouse was generated from an embryonic stem cell (ESC) clone obtained
fromRiken, Japan.GenotypingwasperformedbyTransnetyx, butprimerdetails
andPCRconditionscanbeobtained fromJ.A.NMRIandC57BL/6Jmice (desig-
nated wild-type) purchased commercially were used in a few cases.
IHC
Mouse tissues were fixed in 10% neutral-buffered formalin, dehydrated, and
processed for paraffin wax embedding and sectioning (3 mm). H&E sections
were generated for all samples. IHC was carried out using the EnVision Kit
(Dako) as per the manufacturer’s protocol, with the following antibodies: FH
(Autogen Bioclear), HIF1a (Cayman), insulin (MP Biomedicals), glucagon (MP
Biomedicals and Sigma), and 2SC (Nagai et al., 2007).Cell Reports 20, 3135–3148, September 26, 2017 3145
Intraperitoneal Glucose Tolerance Test
Blood glucose levels were determined with an Accuchek Aviva meter after
16 hr of fasting and at time points following intraperitoneal injection of 2 g
glucose per kilogram of body weight. Animals were culled at the end of the
test, and pancreata were processed as described earlier.
Hormone Secretion and Content Measurements
Insulin secretion was measured by in situ pancreas perfusion or in static incu-
bations of isolated islets (Zhang et al., 2013). Insulin content was determined in
parallel from isolated islets or from mouse pancreata harvested separately.
Quantitative Imaging of ATP, Ca2+, and pHi
Time-lapse imaging of the ATP/ADP ratio in mouse islets was performed using
103–143magnification on a Zeiss AxioZoom.V16 microscope. Islets were in-
fected with an adenovirus (33 104 plaque-forming units [PFUs] per islet) deliv-
ering Perceval, a recombinant sensor of ATP/ADP (Berg et al., 2009). Groups
of islets isolated from CTL and Fh1bKO animals were imaged simultaneously
24 hr post-infection at glucose concentrations as indicated, with single-cell
resolution. Time-lapse images were collected every 30 s, and the bath solution
was perifused at 60 mL/min at 34C.
Simultaneous time-lapse imaging of [Ca2+]i and pHi in mouse islets was per-
formed on the inverted Zeiss AxioVert 200 microscope, equipped with the
Zeiss LSM 510-META laser confocal scanning system, using a 403/1.3 NA
objective. Mouse islets were loaded with 6 mM of the Ca2+-sensitive dye
Fluo-4 for 90 min before being transferred to a separate solution containing
6 mM of the pH-sensitive dye SNARF-5F (both dyes from Molecular Probes)
for a further 50 min at room temperature and imaged using an open chamber
at 34C. The bath solution containing various stimuli was perifused continu-
ously at the rate of 200 mL/min. The ratiometric dye SNARF-5F was excited
at 543 nm, and emission was collected at 650 nm and 600 nm. Fluo-4 was
excited at 488 nm and imaged at 530 nm. Images were acquired at the fre-
quency of 0.03 Hz. The pH calibration of each trace was performed using
the high K+-nigericin technique. Valinomycin (5 mM)was added to the extracel-
lular solution to abolish the K+ gradient (Tarasov et al., 2012, 2013).
Statistical Analysis
Image sequences were analyzed (registration, background subtraction, ROI
intensity versus time analysis) using open-source FIJI software (http://fiji.sc/
Fiji). The numerical time series data were analyzed using the IgorPro pack-
age (Wavemetrics). Statistical significance of the differences between paired
or unpaired samples was tested using Friedman or Kruskall-Wallis tests,
respectively, with Nemenyi post hoc analysis, as implemented in the R pack-
age (R Development Core Team, 2016). Basal pHi was calculated by taking the
mean of the first 15 SNARF-5F ratio values from each cell. After glyceralde-
hyde and 20 mM glucose application, pHi was calculated by taking a mean
of the values when the SNARF-5F ratio reached a nadir. Differences with
p < 0.05 were considered significant. Cells that were not active at 3 mM
glucose and that responded to high glucose with the characteristic [Ca2+]i
oscillations were taken as b cells.
All data are given as mean ± SEM unless indicated that they are mean ± SD.
Other than for image analysis, as indicated earlier, statistical significance was
determined with significance set at <0.05, using either ANOVA with Tukey’s
multiple comparison or Student’s t test (where indicated). Statistical signifi-
cance was determined using GraphPad Prism v.6.0d (GraphPad Software,
La Jolla, CA, USA; http://www.graphpad.com).
Human Islets and Ethics
Pancreatic islets were isolated from deceased donors under ethical approval
obtained from the local human research ethics committees in both Oxford
and Lund. All donors gave informed research consent. Islets were obtained
from the Diabetes Research & Wellness Foundation Human Islet Isolation
Facility, OCDEM, University of Oxford, and the Nordic Center for Clinical
Islet Transplantation (http://www.nordicislets.com; Uppsala, Sweden) via the
Human Tissue Laboratory at Lund University Diabetes Centre. Islets were
hand picked, and their quality was assessed prior to research use. Experi-
ments in Oxford were performed using islets from donors (5 females and
1 male) with the following parameters: age, 47.8 years ± 6.7 years; BMI,3146 Cell Reports 20, 3135–3148, September 26, 201728.4 ± 5.8. In Lund, the characteristics of ND (n = 31, CTL) and diabetic
(n = 7, T2D) islet donors were as follows: age (years), 61.24 ± 10.45 (CTL)
and 60.43 ± 7.72 (T2D), p = 0.82; sex, expressed as male/female, 14/7 (CTL)
and 2/5 (T2D), p = 0.44; BMI, 27.11 ± 3.06 (CTL) and 28.9 ± 5.35 (T2D),
p = 0.42; and HbA1c, 5.85 ± 0.45 (CTL) and 6.41 ± 0.56, p = 0.04. Data are
given asmean ± SD; groups were compared using the Student’s t test or using
two-tailed Fisher’s exact test.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and two tables and can be found with this article online at
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This paper is a tribute to Dr. Patrick John Pollard, who died unexpectedly in
June 2015. He was an enthusiastic and exceptionally gifted scientist. We
remember him fondly as a friend and colleague who made important contribu-
tions, not only to this study, but also to the field of cancer metabolism.
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Supplemental Experimental Procedures 
 
RNA isolation, reverse transcription and quantitative PCR (qPCR) 
Total RNA was extracted from freshly-picked size-matched islets using Tri-reagent (Sigma) according to the 
manufacturer's protocol. Single-strand cDNA was synthesized from total RNA (2 µg) using a high-capacity 
cDNA kit (Applied Biosystems) and analyzed by multiplex qPCR using Taqman gene expression assays on a 
StepOne thermocycler (Applied Biosystems). Normalization was to β-actin mRNA and relative gene expression 
was calculated using the ΔΔCT method. DNA corresponding to 50 ng of RNA template was used and three 
biological replicates, each in duplicate, were performed for each experiment. Statistical comparisons were 
performed using an unpaired Student’s t test. 
 
Mouse Islet Isolation, culture and hormone secretion 
Islets were isolated by collagenase (Sigma) or liberase (Roche) digestion. Collagenase or liberase was injected 
into the pancreas, which was then excised and incubated for 10-14 min at 37oC.  Digestion was stopped by the 
addition of 10 ml of ice-cold Hank’s Balanced Salt (HBSS; Sigma UK) supplemented with 0.1% bovine serum 
albumin (BSA) (Invitrogen, UK). The islets were left to sediment by gravity and washed further in HBSS with 
BSA to remove the remaining exocrine tissue. Mouse islets were transferred to RPMI-1640 (Sigma, UK) 
supplemented with 5 mM glucose, 100 U/ml penicillin, 10 µg/ml streptomycin and 10% fetal calf serum. 
Isolated mouse islets were cultured in this medium at 37 oC in a humidified atmosphere (5% CO2/95% air) for 2 
hr prior to experiments. 
 
Hormone secretion was measured from batches of 10-12 islets and was counted as an experiment (unless 
otherwise stated). Size-matched islets were hand-picked and washed twice in glucose-free RPMI-1640 (Sigma; 
supplemented with 100 U/ml penicillin, 10 µg/ml streptomycin and 10% fetal calf serum). The islets were pre-
incubated for 1 hr in a humidified chamber at 37 oC (5% CO2/95% air) in 300µl of Krebs-Ringer buffer (KRB) 
which contained the following (mM) 140 NaCl, 3.6 KCl, 2.6 CaCl2, 0.5 MgSO47H2O, 0.5 NaH2PO4, 2 NaHCO3, 
5 HEPES and 2 mg/ml BSA (pH adjusted to 7.4) and 1 mM glucose. The pre-incubation buffer was discarded 
and the islets were incubated for a further 1 hr, as indicated. In one set of experiments (Figure 3E), hormone 
secretion was measured in the presence of 70 mM KCl (indicated in the text) to bypass electrical activity and 
investigate the amplifying effect of glucose. 
 
An aliquot of the supernatant was collected and stored at -20oC for quantification of insulin or glucagon 
secretion by radioimmunoassay. The remaining supernatant was discarded and the islets were lysed in 100 µl of 
ice-cold acid ethanol solution (containing ethanol, H2O and HCl in a ratio of 52:17:1) to release their hormone 
content. The lysates were immediately frozen at -20 oC. Radio-immunoassays for insulin and glucagon were 
performed using kits (Millipore and Eurodiagnostica respectively) following the manufacturer’s protocols. 
 
Insulin and glucagon content of whole pancreas was determined by freezing and then grinding the pancreas, 
after weighing. This ground tissue was then transferred to ice-cold acid ethanol (as per above) and sonicated 
prior to determination of hormone content. 
 
Whole-pancreas perfusion 
Dynamic measurements of insulin secretion were performed using in situ pancreatic perfusion. Briefly, the aorta 
was cannulated by ligating above the coeliac artery and below the superior mesenteric artery, and the pancreas 
was perfused with KRB solution at a rate of ~0.45 ml/min using an Ismatec Reglo Digital MS2/12 peristaltic 
pump. The perfusate was maintained at 37 oC with a Warner Instruments temperature control unit TC-32 4B in 
conjunction with a tube heater (Warner Instruments P/N 64-0102) and a Harvard Apparatus heated rodent 
operating table. The effluent was collected, using a Teledyne ISCO Foxy R1 fraction collector. The pancreas 
was first perfused for 20 min with 1 mM glucose before commencing the experiment to establish the basal rate 
of secretion. 
 
Membrane potential recordings 
Freshly isolated mouse islets were immobilized by using a large bore glass electrode and electrical activity was 
measured from β cells on the periphery of the islets using an EPC-10 amplifier (HEKA Electronics) and Pulse 
software (version 8.81, HEKA Electronics). β-cells were identified by Na+ current inactivation pattern and 
electrical activity in response to different glucose concentrations. In order to maintain metabolically intact cells, 
perforated patch whole-cell configuration was used. The extracellular solution is composed of (mM) 140 NaCl, 
3.6 KCl, 0.5 MgSO4, 0.5 NaH2PO4, 1.5 CaCl2, 5 NaHCO3 and 10 HEPES (pH7.4 with NaOH). The intracellular 
solution contained (mM) 76 K2SO4, 10 NaCl, 10 KCl, 1 MgCl2 and 5 HEPES (pH 7.35 with KOH). Perforation 
was achieved by the pore-forming antibiotic amphotericin B (at the final concentration of 40 µg/ml) added into 
the intracellular solution. 
 
Measurement of [5-3H]-glucose utilization and [U-14C]-glucose oxidation 
Groups of islets were incubated in KRB containing BSA (Sigma, 0.2%) and 1 or 20 mM glucose at 37 °C for 90 
min in vials. Metabolism was stopped by the addition of HCl. The CO2 produced during oxidation was captured 
in 400 µl phenylethylamine (Sigma), diluted 1:1 v/v in methanol, during a 90 min incubation period. The 3H2O 
produced was left to equilibrate to 2 ml water added to the vials, for a further 24 hr. Biodegradable scintillation 
liquid (10 ml) was then added to either the 400 µl phenylethylamine or to the 2 ml H2O, in a scintillation vial. 
The 14CO2 and the 3H2O were measured in a scintillation counter. Radiolabeled glucose and scintillation liquid 
were obtained from Perkin Elmer. 
 
HPLC quantification of amino acids 
Islet amino acids were separated by reverse-phase HPLC after pre-column derivatization with o-
phthaldialdehyde and quantified by fluorescence detection. Groups of 30 islets were analyzed in triplicate from 
Stage II Fh1βKO and CTL littermates. The content and release of the measured islet amino acids were studied 
following previously published methods (Hernandez-Fisac et al, 2006). The residual incubation medium was 
aspirated, the islets were washed twice with 100 l PBS and their amino acids extracted with 30 μl of 10% (w/v) 
5-sulfosalicylic acid. 
 
Metabolite analysis (CE-TOFMS) of islets 
The levels and pattern of incorporation of the respective labels in metabolites (fmol/cell) were determined by 
capillary electrophoresis time of flight mass spectrometry (CE-TOFMS) analysis. Isolated Islets from individual 
mice of the same genotype were pooled and then separated into experimental groups. These islets were then 
washed and incubated at 37 oC in replicates under appropriate experimental conditions. Labelling studies were 
performed on islets isolated from Stage II Fh1βKO and age-matched CTL mice and cultured in RPMI-1640 
(Sigma, UK) medium supplemented with 100 U/ml penicillin, 10 µg/ml streptomycin and 10% fetal calf serum 
containing either the stable isotope tracer [U-13C5]-glutamine for 3 hr or 13C6-glucose for 1 hr at 1 or 20 mM 
glucose. At the end of the incubation, the islets were washed twice in an excess of 5% mannitol in water (Wako) 
and 200 µl of methanol was added containing 3 standards (methionine sulfone, 2-morpholinoethanesulfonate 
and D-Camphor-10-sulfonic acid, each at 25 µM). The islets were then left to rest for 10 min prior to freezing 
and storage at -80 oC. Frozen islet samples were prepared and analyzed by CE-TOFMS as described previously 
(Soga et al, 2006; Soga et al, 2009). 
 
Electron microscopy and comparative quantitation of mitochondria 
Isolated islets from Stage II CTL and Fh1βKO mice were fixed in 2.5% glutaraldehyde (Sigma, UK) in 0.1 M 
phosphate buffer, post-fixed in 1% osmium tetroxide, block stained in 2% uranyl acetate and embedded in 
Spurr’s resin or London Resin Gold resin (LRG) (Agar Scientific, UK). Ultrathin sections were cut onto nickel 
grids, contrast was enhanced with 2% uranyl acetate and lead citrate and sections examined in a Joel 1010 
microscope. For morphometry, mitochondrial cytoplasmic density and sectional area (size) were quantified from 
micrographs (x800 magnification) taken of 25-30 β cells in 3-5 islets from each experimental group.  
 
Culture of human islets and CE-TOFMS 
Human pancreata (Figure 5E and Table S2) were obtained with ethical approval and clinical consent from non-
diabetic donors. Islets were isolated in the Diabetes Research & Wellness Foundation Human Islet Isolation unit 
(Oxford, UK) using modified versions of published procedures (Lake et al., 1989). Following isolation, islets 
were cultured in CMRL medium containing 5.5 mM glucose and 2 mM L-glutamine. Hand-picked islets were 
size-matched and cultured for 1 or 24 hr in RPMI containing glucose as indicated. Islets were pre-incubated in 
Krebs-Ringer buffer (KRB) containing 2 mg/ml BSA and 3 mM glucose for 1 hr at 37 °C, followed by a 1 hr 
test incubation in KRB supplemented with glucose as indicated. At the end of the incubation time the islets were 
processed for CE-TOFMS as described above for mouse islets. 
 
Culture of human islets and GC/MS analysis 
For these experiments (Figure 5F), human islets were obtained from the Nordic Center For Clinical Islet 
Transplantation (Uppsala, Sweden). Experimental procedures were approved by the Lund University Ethical 
Board. These were in compliance with the Declaration of Helsinki (2000) and the World Medical Association. 
Islets were processed according as previously described (Fadista et al., 2014). Islets were incubated 30 min at 
2.8 mM glucose and then stimulated with either 2.8 or 16.7 mM glucose for 1 hr. The islets were transferred into 
300 μl ice-cold extraction solvent. Metabolite extracts were analyzed on an Agilent 6890N gas chromatograph 
(Agilent Technologies, Atlanta, GA) equipped with an Agilent 7683B auto-sampler (Agilent Technologies) and 
coupled to a LECO Pegasus III TOFMS electron impact time-of-flight mass spectrometer (LECO Corp., St. 
Joseph, MI). 
 
Immunofluorescence and immunoblotting 
Immunofluorescence was performed using the same antibodies as for IHC with Alexa Fluor® secondary 
antibodies (Molecular Probes, Life technologies) and an FITC-conjugated anti-V5 antibody (Life technologies) 
using a Zeiss LSM510 META confocal imaging system. 
 
Immunoblotting was performed as described previously (O'Flaherty et al., 2010) using primary antibodies 
against FH (Autogen Bioclear) and calnexin (Calbiochem). 
 
Mass spectrometry (MS) and Proteome analysis 
Isolated pancreatic islets were lysed in 7 M Urea /SDS buffer and either run on an SDS-PAGE or processed in 
solution. For in solution samples, depletion of serum albumin was achieved by addition of ice-cold ethanol to a 
final concentration of 42% to the lysates and reconstitution of protein pellets in a buffer containing 6 M urea and 
100 mM Tris (pH 7.8). Unmodified cysteine residues were alkylated in reducing conditions (10 mM DTT) using 
30 mM 4-vinylpyridine (resulting in pyridylethylation, PE) or 50 mM iodoacetamide (carbamidomethylation, 
CA). Proteins were then subjected to trypsin digestion. In solution samples were further purified on Sep-Pak 
C18 columns (Waters). 
 
Analysis of resulting peptides was performed on either an LTQ Orbitrap Velos or a Q-Exactive (Thermo Fisher 
Scientific). 
 
LTQ Orbitrap Velos 
Peptides were separated on an Acquity nano UPLC system (Waters) supplemented with a 25 cm C18 column, 
1.7 µm particle size (Waters). They were eluted by applying a 60-180 min linear gradient from 1% buffer A 
(0.1% formic acid in water) to 40% buffer B (0.1% formic acid in acetonitrile) at a flow rate of 250 nl/min. 
Collision-induced dissociation (CID) was induced on the twenty most abundant ions per full MS scan using an 
isolation width of 1.5Da. All fragmented precursor ions were actively excluded from repeated MS/MS analysis 
for 15 s. 
 
Q-Exactive 
Peptides were separated on a Ultimate 3000 RSLCnano System utilizing a PepMap C18 column, 2 µm particle 
size, 75 µm x 50 cm (Thermo Scientific). A 60 min linear gradient was applied from 1% buffer A (0.1% formic 
acid, 5% DMSO in water) to 40% buffer B (0.1% formic acid, 5% DMSO in acetonitrile) at a flow rate of 250 
nl/min. Collision-induced dissociation (CID) was induced on the fifteen most abundant ions per full MS scan 
using an isolation width of 1.5 Da. All fragmented precursor ions were actively excluded from repeated MS/MS 
analysis for 15 s. 
 
All samples were analyzed in triplicate. Feature identification was performed by generation of Mascot generic 
files (mgf) using Proteowizard and analysis with either Mascot v2.3.01 or Peaks 7 searching the human or 
mouse SwissProt database. 
 
Normalisation of MS runs and label-free quantitation of detected features was performed using Peaks 7 
(Bioinformatics solutions). All features with a significant change between both conditions (ANOVA p-value < 
0.05) were included in the analysis and imported to Ingenuity. 
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Figure S1. Introduction of full length (FH) and cytoplasmic (FHcyt) human fumarate hydratase rescues 
dysregulated metabolism in Fh1βKO islets. Related to Figure 1.
(A) Deletion of Nrf2 did not alter the glucose tolerance in Stage II Fh1βKO compared to littermate CTL mice. 
IPGTT was performed in Fh1βKONrf2CTL, Fh1βKONrf2Het, Fh1βNrf2DKO and age matched CTL, 
Fh1CTLNrf2KO and Fh1CTLNrf2Het mice (n= 3 experiments using a total of at least 8 mice per genotype). 
#p<0.05, ##p<0.01 and ###p<0.001 between Fh1CTL and Fh1βKO groups irrespective of whether mice were 
heterozygous for Nrf2 (Nrf2Het) or Nrf2 was deleted (Nrf2KO).
(B-D) Analysis of gene expression by qPCR in isolated islets from Stage II CTL (blue), Fh1βKO (red), Fh1β
KO+FH (green) and Fh1βKO+FHcyt (brown) mice for murine fumarate hydratase, Fh1 (B), Egl-9 family 
hypoxia-inducible factor 3, Egln3 (C), and heme oxygenase-1, Hmox1 (D) (n=3 experiments using islets from at 
least 9 mice per genotype). These data confirm that although murine Fh1 remains deleted in the β-cells of Fh1βKO, 
Fh1βKO+FH and Fh1βKO+FHcyt mice, the Hif1α target gene Egln3 and the Nrf2 target gene Hmox1 both show 
mRNA expression in islets from Fh1βKO+FH and Fh1βKO+FHcyt mice comparable to that of CTL islets by virtue 
of expression of both full length and cytoplasmic-specific human FH. In contrast, the mRNA levels of Egln3 and 
Hmox1 are elevated in the Fh1βKO islets because of elevated fumarate leading to the subsequent stabilization of 
both HIF1α and NRF2. mRNA levels were normalized to those of Actb. #p<0.0001 versus CTL. Error bars indicate 
± SEM.
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Figure S2. Glucose stimulated insulin secretion is blunted in Fh1βKO islets. Related to Figure 2.
Insulin secretion in age-matched CTL and Stage II Fh1βKO islets following 1 hr stimulation with glucose or 
α-ketoisocaproic acid (α-KIC; 10 mM). Results are displayed with insulin secretion expressed normalized to a 
percentage of the basal value (2 mM glucose). Approximate basal secretion is indicated (dashed line), (n=islets 
from at least 3 mice per genotype). ***p<0.001 versus 2 mM glucose CTL, §§p<0.01, §§§p<0.001 for compari-
son of the same condition between FH1βKO and CTL. Error bars indicate ± SEM.
Figures in the main text display insulin secretion data as absolute values. 
Data have been normalized to the basal insulin release to compensate for any decrease in secretion due to lowered 
insulin content. The fact that stimulated insulin secretion remains strongly reduced in Fh1βKO islets argues that 
there is a functional defect.
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Figure S3. Glucose stimulated amino acid response in CTL and Fh1βKO islets. Related to Figure 3.
(A-B) Analysis by CE-TOFMS of islet content of significant metabolites from Stage II CTL (blue), Fh1βKO 
(red), Fh1βKO+FH (green) and Fh1βKO+FHcyt (brown) mice demonstrated that β cell fumarate (A) and 
argininosuccinate (B) contents were normalized to levels comparable to CTL mice following re-expression of 
full-length or cytoplasmic-specific human FH. #p<0.0001 versus CTL; ND not detected. (n=3 samples from 
12-15 mice per experimental group).
(C-D) Amino acid content measured by HPLC in Stage II CTL (n=8 mice) and Fh1βKO (n=12 mice) islets after 
culture in 1 mM glucose (C) or 20 mM glucose (D) for 1 hr. (n=30 islets per genotype were analyzed in triplicate 
in 5 experiments). Abbreviations: Asp, aspartate; Glu, glutamic acid; Ser, serine; Gln, glutamine; His, histidine; 
Gly, glycine; Thr, threonine; Arg, arginine; Tau, taurine; Ala, alanine; Tyr, tyrosine; GABA, gamma aminobutyric 
acid; Val, valine; Phe, phenylalanine; Ile, isoleucine and Leu, leucine. Error bars represent ± SEM.
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Figure S4. Metabolite analysis with stable isotope tracer [U-13C5]-glutamine or 13C6-glucose of murine 
Fh1βKO islets and CTL islets. Related to Figure 3.
(A-O) Analysis by CE-TOFMS of metabolite levels (relative area) and the pattern of 13C incorporation in islets 
isolated from age-matched CTL (black) and Stage II Fh1βKO (grey) mice following culture in medium 
containing either[U-13C5]-glutamine for 3 hr (A-H and M) or 13C6-glucose for 1 hr (I-L and N-O) in cells and 
stimulation at 1 or 20 mM glucose. The samples are underivatized and uncorrected for natural abundance of 
13C.
(M) Changes in the percentage incorporation by glucose stimulation (1 and 20 mM glucose; 1G and 20G) of 
glutamine isotopomers (m0 to m+5) into UDP-N-acetylglucosamine following culture for 3 hr of isolated CTL 
and Fh1βKO islets in medium containing the stable isotope [U-13C5]-glutamine.
(N) Changes in the percentage incorporation by glucose stimulation (1 and 20 mM glucose) of glucose 
isotopomers (m0-m+6) into glutamate following culture for 1 hr of isolated CTL and Fh1βKO islets in medium 
containing the stable isotope 13C6-glucose.
(O) Changes in the percentage incorporation by glucose stimulation (1 and 20 mM glucose) of glucose 
isotopomers (m0-m+6) into aspartate following culture for 1 hr of isolated CTL and Fh1βKO islets in medium 
containing the stable isotope 13C-glucose.
(n=3 experimental groups of pooled islets for each experimental condition from at least 3 mice per genotype).
These data indicate that at 1 mM glucose none of the intracellular glutamate is derived from glutamine in CTL 
islets compared to ~50% in Fh1βKO islets. At 20 mM glucose, both the CTL and Fh1βKO islets use glutamine 
to produce glutamate. The small amount of islet tissue that could be isolated precluded a broad-spectrum 
analysis. However, at 1 mM glucose (1G) essentially none of the glutamate in the CTL islets came from 
labelled glutamine. By contrast, ~50% of the glutamate is derived from glutamine in Fh1βKO islets as label 
travels via the oxidative route of the Krebs cycle into fumarate and argininosuccinate. Most of this is from the 
direct conversion of glutamine to glutamate (m+5), but detection of m+3 may result from entry of fumarate 
into the urea cycle, allowing Asp m+4 to be produced. At 20 mM glucose, both the CTL and Fh1βKO islets use 
glutamine to produce glutamate, and both m+5 and m+3 are observed.
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Figure S5. Introduction of full length (FH) or cytoplasmic (FHcyt) human fumarate hydratase restores 
mitochondrial morphology in β cells lacking Fh1. Related to Figure 4.
(A) Electron micrographs of β cells in Stage II CTL and Fh1βKO islets highlighting some very large mitochondria 
(red arrow) and smaller mitochondria (blue arrow) in the Fh1βKO β cells compared to CTL islets. Abbreviations: g, 
secretory granule; m, mitochondrion; n, nucleus. Scale bar: 500 nm.
(B) Relative mitochondrial area (mitochondrial area divided by cytoplasmic area; maximum to minimum range) 
compared in β cells in Stage II CTL (blue), Fh1βKO (red), Fh1βKO+FH (green) and Fh1βKO+FHcyt (brown) mice 
showing the larger range of mitochondrial areas in Fh1βKO islets and normalization following reintroduction of 
FH. (n=25-30 β cells in 3-5 islets per genotype). Error bars represent ± SEM.
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Figure S6. Evidence of elevated protein succination in pancreatic islets from Fh1βKO mice and human 
diabetic donors. Related to Figure 5.
(A) MS/MS spectra for peptide 178VGVGPGSVCTTR189 showing increased succination in guanosine 
5′-monophosphate oxidoreductase (GMP reductase 1) at cysteine 186 (C186) in Stage II Fh1βKO islets. Both 
theoretical mass and detected mass (in brackets) are given for each assigned fragment ion. Peptide fragments of 
different mass that contain the modified residue are highlighted in red. PE indicates the modification of cysteine 
residues at C186 to pyridylethyl-cysteine.
(B) MS/MS spectra showing either succination (2SC) or carbamidoethylation (CAC) at cysteine 106 (C106) in the 
100
GLIAAICAGPTALLAHEIGFGSK122 peptide of human DJ-1 derived from islets of a T2D donor. Matching 
fragment ion peaks between the two peptide species that do not contain the modified residue are highlighted in 
green, whereas peptide fragments of different mass that contain the modified residue are highlighted in red.
The calculated peptide mass based on the detected m/z (m: mass, z: charge) value of the doubly charged precursor 
peptide ion ([M+2H]++) and the calculated ([M] calc.) and theoretical peptide mass ([M] theor.) are stated for both 
peptide species. Detected N- and C-terminal fragment ions are indicated in the peptide sequence, assigned in the 
spectrum and depicted as follows: b: N-terminal fragment ion; y: C-terminal fragment ion; *: fragment ion minus 
NH3; and 
++: doubly charged fragment ion. Both theoretical mass (in brackets) and detected mass are given for 
each assigned fragment ion.
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Figure S7. Glyceraldehyde blunts GSIS in CTL islets. Related to Figures 5 and 6.
(A) Insulin secretion measured during 1 hr incubations at 1, 6 and 20 mM glucose following 24 hr culture of 
wild-type islets from C57BL/6J mice with 10 mM glyceraldehyde. (n=6 experimental groups of islets for each 
condition assayed in 2 experiments; islets harvested from 6 mice in total). Data are mean values ± SEM of 
secretion expressed as per cent of hormone content. ****p<0.0001 versus 1 mM glucose; ¶¶¶¶p<0.0001 versus 
6 mM glucose; §§§§p<0.0001 comparing same condition between groups.
(B) Insulin content of the islets in A.
  
Metabolite WT WT WT WT WT WT WT WT KO KO KO KO KO KO KO T-test 
Argininosuccinate 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 9.19E-01 8.75E-01 9.39E-01 9.58E-01 9.13E-01 9.57E-01 8.28E-01 8.72E-17 
Fumarate 6.53E-02 7.15E-02 1.22E-01 6.28E-02 6.81E-02 1.34E-01 7.82E-02 5.63E-02 1.20E+00 1.05E+00 1.06E+00 1.15E+00 1.21E+00 1.25E+00 1.16E+00 1.45E-14 
Glucose-6-phosphate 2.46E-02 5.92E-02 4.63E-02 3.91E-02 3.26E-02 3.90E-02 3.86E-02 3.21E-02 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 3.39E-02 7.42E-05 
Aspartate 1.26E+00 1.41E+00 1.54E+00 1.31E+00 1.19E+00 1.41E+00 1.33E+00 1.17E+00 1.06E+00 8.90E-01 8.96E-01 1.09E+00 1.09E+00 1.02E+00 1.08E+00 1.09E-04 
Adenylosuccinate 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 7.07E-02 6.39E-02 5.89E-02 1.99E-01 7.08E-02 8.88E-02 1.44E-01 1.27E-04 
Cysteine-glutathione 
disulphide -Divalent 8.49E-02 1.02E-01 1.09E-01 6.87E-02 3.75E-02 9.96E-02 6.01E-02 9.32E-02 6.97E-02 5.69E-02 0.00E+00 1.80E-02 4.40E-02 2.47E-02 1.84E-02 2.07E-03 
Adenosine 
monophosphate 3.85E-01 5.45E-01 5.70E-01 2.40E-01 3.68E-01 6.06E-01 4.10E-01 2.74E-01 1.13E-01 1.80E-01 1.26E-01 3.26E-01 2.23E-01 9.76E-02 2.97E-01 2.29E-03 
Cystathionine 2.02E-01 2.18E-01 2.79E-01 1.91E-01 1.85E-01 2.90E-01 1.83E-01 3.62E-01 3.95E-01 3.60E-01 3.85E-01 3.51E-01 3.18E-01 2.70E-01 3.19E-01 3.37E-03 
Uridine 
monophosphate 9.10E-02 1.35E-01 1.31E-01 6.77E-02 1.15E-01 1.75E-01 1.24E-01 8.39E-02 0.00E+00 0.00E+00 0.00E+00 1.06E-01 7.35E-02 3.50E-02 1.05E-01 6.30E-03 
Guanidinoacetate 5.13E-02 1.23E-01 1.22E-01 6.01E-02 5.36E-02 9.18E-02 1.02E-01 9.68E-02 5.64E-02 4.67E-02 0.00E+00 6.31E-02 5.47E-02 5.22E-02 5.48E-02 9.36E-03 
Gamma 
aminobutyricacid 5.33E-01 7.11E-01 8.16E-01 7.00E-01 5.59E-01 7.92E-01 8.52E-01 6.80E-01 5.38E-01 4.27E-01 5.24E-01 5.85E-01 6.51E-01 5.04E-01 6.46E-01 1.21E-02 
Proline 4.20E-01 4.94E-01 6.34E-01 5.39E-01 3.69E-01 5.79E-01 5.25E-01 5.01E-01 5.25E-01 3.40E-01 3.57E-01 3.85E-01 4.12E-01 3.78E-01 3.84E-01 1.32E-02 
 Metabolite WT WT WT WT WT WT WT WT KO KO KO KO KO KO KO T-test 
cis-Aconitate 3.12E-01 2.00E-01 8.11E-02 1.50E-01 1.14E-01 1.16E-01 1.74E-01 2.73E-01 2.48E-01 4.36E-01 6.46E-01 2.32E-01 3.24E-01 2.47E-01 2.88E-01 1.61E-02 
Guanosine 
monophosphate 1.63E-01 2.64E-01 2.72E-01 1.30E-01 1.47E-01 3.75E-01 1.99E-01 1.62E-01 0.00E+00 1.29E-01 0.00E+00 2.25E-01 1.01E-01 0.00E+00 1.77E-01 1.78E-02 
Glycine 7.74E-01 8.17E-01 1.13E+00 9.82E-01 7.38E-01 9.04E-01 9.38E-01 7.81E-01 1.11E+00 9.61E-01 1.05E+00 9.93E-01 1.08E+00 9.74E-01 9.92E-01 2.21E-02 
Glucose 1-phosphate 9.78E-02 1.16E-01 1.47E-01 1.05E-01 5.91E-02 9.12E-02 9.92E-02 9.52E-02 8.20E-02 7.47E-02 6.40E-02 4.43E-02 1.01E-01 9.05E-02 5.39E-02 3.03E-02 
Isocitrate 6.27E-01 4.60E-01 1.57E-01 4.03E-01 2.00E-01 1.47E-01 3.55E-01 4.76E-01 4.75E-01 7.13E-01 1.09E+00 4.79E-01 5.49E-01 4.15E-01 5.01E-01 3.35E-02 
Glycero-
phosphorylcholine 4.44E-01 5.25E-01 6.75E-01 6.77E-01 3.99E-01 6.25E-01 7.73E-01 6.96E-01 5.94E-01 5.88E-01 7.59E-01 8.09E-01 7.48E-01 9.04E-01 9.57E-01 3.70E-02 
 
Table S1. Metabolite analysis of murine Fh1βKO islets compared to CTL islets confirms Fh1 loss leads to dysregulated metabolism. Related to Figure 3. 
Analysis by CE-TOFMS of islet cellular concentrations (fmol/cell) for metabolites. Islets were isolated from individual Stage II Fh1βKO (n=7) and age-matched CTL (n=8) mice and 
incubated for 1 hr in 5 mM glucose then prepared for CE-TOFMS as described above. Metabolites listed show significance of p<0.05 or better between CTL and Fh1βKO islets (Student’s 
t-test).
 Table S2. Screening protein succination in Fh1βKO murine islets, non-diabetic and T2D human 
islets by mass spectrometry. Related to Figure 5. 
This list of proteins was established using a false discovery rate of 1%. Protein sequence was 
confirmed on http://www.uniprot.org/. Quantitative analysis of protein changes was determined using 
Peaks (Bioinformatics solutions) and the proteins that were detected with significant change of 
abundance between both conditions are listed. P is the probability that the match between the MS/MS 
query and the peptide sequence is random. (n=150 islets isolated from 3 Stage II Fh1βKO mice; 
approximately 150 islets from each of 2 diabetic and 2 nondiabetic adult donors). 
